Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Colorectal Neoplasms 325Pancreatic Neoplasms 189Carcinoma, Hepatocellular 119Stomach Neoplasms 116Colonic Neoplasms 87Esophageal Neoplasms 85Carcinoma, Non-Small-Cell Lung 84Breast Neoplasms 80Rectal Neoplasms 78Ovarian Neoplasms 65Neoplasm Metastasis 61Lung Neoplasms 61Neoplasms 57Cholangiocarcinoma 55Liver Neoplasms 47Melanoma 46Gastrointestinal Neoplasms 46Prostatic Neoplasms 43Biliary Tract Neoplasms 37Endometrial Neoplasms 34Squamous Cell Carcinoma of Head and Neck 32Sarcoma 32Carcinoma, Renal Cell 30Esophageal Squamous Cell Carcinoma 28Uterine Cervical Neoplasms 27Head and Neck Neoplasms 25Adenocarcinoma Of Esophagus 24Urinary Bladder Neoplasms 23Small Cell Lung Carcinoma 20Triple Negative Breast Neoplasms 17

Interventions

lenvatinib 1Paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Advanced Gastric or Gastroesophageal Junction Adenocarcinoma × Gastrointestinal × 30 days × Clear all
NCT05585580 2026-05-26

Second-line Treatment With Serplulimab, Lenvatinib, and Paclitaxel in Advanced Gastric Cancer After Prior Immunotherapy

Qilu Hospital of Shandong University

Phase 2 Active not recruiting
59 enrolled
Gastrointestinal

Advanced Gastric or Gastroesophageal Junction Adenocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡